Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee.

Archive ouverte

Onida, Francesco | Gagelmann, Nico | Chalandon, Yves | Kobbe, Guido | Robin, Marie | Symeonidis, Argiris | de Witte, Theo | Itzykson, Raphael | Jentzsch, Madlen | Platzbecker, Uwe | Santini, Valeria | Sanz, Guillermo | Scheid, Christof | Solary, Eric | Valent, Peter | Greco, Raffaella | Sánchez-Ortega, Isabel | Yakoub-Agha, Ibrahim | Pleyer, Lisa

Edité par CCSD ; American Society of Hematology -

International audience. Chronic myelomonocytic leukemia (CMML) is a heterogeneous disease presenting with either myeloproliferative or myelodysplastic features. Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only potentially curative option, but the inherent toxicity of this procedure makes the decision to proceed to allo-HCT challenging, particularly because patients with CMML are mostly older and comorbid. Therefore, the decision between a nonintensive treatment approach and allo-HCT represents a delicate balance, especially because prospective randomized studies are lacking and retrospective data in the literature are conflicting. International consensus on the selection of patients and the ideal timing of allo-HCT, specifically in CMML, could not be reached in international recommendations published 6 years ago. Since then, new, CMML-specific data have been published. The European Society for Blood and Marrow Transplantation (EBMT) Practice Harmonization and Guidelines (PH&G) Committee assembled a panel of experts in the field to provide the first best practice recommendations on the role of allo-HCT specifically in CMML. Recommendations were based on the results of an international survey, a comprehensive review of the literature, and expert opinions on the subject, after structured discussion and circulation of recommendations. Algorithms for patient selection, timing of allo-HCT during the course of the disease, pretransplant strategies, allo-HCT modality, as well as posttransplant management for patients with CMML were outlined. The keynote message is, that once a patient has been identified as a transplant candidate, upfront transplantation without prior disease-modifying treatment is preferred to maximize chances of reaching allo-HCT whenever possible, irrespective of bone marrow blast counts.

Consulter en ligne

Suggestions

Du même auteur

The ABNL-MARRO 001 study: a phase 1–2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes

Archive ouverte | Moyo, Tamara | CCSD

International audience. Abstract Background Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) comprise several rare hematologic malignancies with shared concomitant dysplastic and proliferative clinicopathologi...

Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults

Archive ouverte | Itzykson, Raphael | CCSD

International audience

Outcomes of CMML patients undergoing allo-HCT are significantly worse compared to MDS-a study of the CMWP of the EBMT.

Archive ouverte | Rovó, Alicia | CCSD

International audience. Although CMML since long has been separated from MDS, many studies continue to evaluate the outcomes of both diseases after hematopoietic cell transplantation (allo-HCT) together. Data evalua...

Chargement des enrichissements...